DalCor Announces Appointment of Paul R. Fonteyne to Chairman of the Board
LONDON and MONTREAL, March 07, 2019 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the appointment of Paul R. Fonteyne to Chairman of the Board effective February 27, 2019.
“I am delighted to pass the baton to Paul Fonteyne who will assume the Chairmanship of DalCor,” said Robert McNeil, Ph.D., Chairman, DalCor. “Paul’s pharmaceutical experience, track record of success, understanding of the global healthcare environment, and commitment to driving innovation makes him uniquely qualified to help guide DalCor through the next phases as we follow the fully randomized dal-GenE trial through to data.”
Mr. Fonteyne will assume the position from Robert McNeil, Ph.D., who will continue to serve on the DalCor board. In his positions as Co-Founder with Jean-Claude Tardif of the Montreal Heart Institute, Founding Chief Executive Officer and Chairman, Dr. McNeil has ensured DalCor is in an excellent position to continue the development of dalcetrapib as a potential innovative precision medicine treatment for cardiovascular diseases.
“This is an exciting time to join DalCor,” said Paul Fonteyne. “Together with the DalCor board and the management team, I look forward to building on the promise of precision medicine in cardiovascular disease to improve patient’s outcomes.”
With more than 30 years of global pharmaceutical experience, Paul Fonteyne’s career spans over three decades of leadership roles across North America and Europe with companies including Boehringer-Ingelheim, Merck, and Abbott Laboratories. Until 2018, he was President and CEO, Boehringer-Ingelheim USA. He is past board member of the National Pharmaceutical Council and PhRMA. He serves on the boards of ResTORbio Inc., Gelesis Inc, and Ypsomed AG. Mr. Fonteyne holds an MBA from Carnegie-Mellon University, Pittsburgh, and a degree in Chemical Engineering from the University of Brussels.
DalCor is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s first development program, dalcetrapib, is intended to reduce cardiovascular events and deliver superior cardiovascular outcome in a specific genetic subset of patients.
DalCor holds the worldwide exclusive license for dalcetrapib, together with rights to the genetic marker for use with dalcetrapib. The dal-GenE study is now fully randomized with more than 6,000 patients with data expected in 2021. For more information, visit www.dalcorpharma.com.
Allison Blum, Ph.D.
LifeSci Public Relations
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Tricentis Disrupts RPA Market with Resilient Model-Based Automation22.5.2019 17:00:00 CEST | Pressemelding
Model-based automation technology trusted by 1600+ enterprise organizations now drives a dedicated Tricentis RPA offering MOUNTAIN VIEW, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Tricentis today announced the availability of Tricentis RPA, which is differentiated by its award-winning model-based automation technology and radically simplified bot pricing model. Tricentis’ model-based automation technology has over 12 years of research and development behind it, and is currently leveraged by 1600+ enterprise organizations. It is best known for delivering highly-resilient end-to-end automation of complex business processes—supporting over 150 enterprise technologies, from legacy applications to the most modern SaaS-based apps. “To satisfy rapidly-changing customer expectations, organizations must be able to change existing processes and applications with both agility and confidence,” explained Tricentis Founder and Chief Strategy Officer Wolfgang Platz. “They need to know that the automati
LGC Capital announces that it has increased its ownership to 40.4% of Little Green Pharma in Australia22.5.2019 16:25:00 CEST | Pressemelding
MONTRÉAL, May 22, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) announces that after much negotiation, it has successfully acquired, from a non-executive founder, additional shares in Australia’s licensed medical cannabis producer Little Green Pharma (LGP) bringing its ownership from 14.1% up to 40.4%. LGP was the first, and is currently the only, domestic cannabis company in Australia producing a locally grown medicinal cannabis medicine for patients. LGC believes the opportunity to increase its ownership in LGP creates significant value for its shareholders and enables the Corporation to further take part in the rapidly expanding Australian medical cannabis market. Little Green Pharma has had over 400 patients approved in Australia, with new patients increasing exponentially month-over-month. The Australian industry represents one of the fastest growing international medical cannabis markets globally, with approximately 6,400 SAS B f
Virtusa recognized as a Visionary in the Magic Quadrant for CRM and Customer Experience Implementation Services, Worldwide22.5.2019 16:05:00 CEST | Pressemelding
SOUTHBOROUGH, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS:VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, today announced that Gartner, Inc. has positioned Virtusa in the Visionaries Quadrant of the 2019 Magic Quadrant for CRM and Customer Experience (CX) Implementation Services, Worldwide. The report evaluated Virtusa along with 17 other companies in CRM and Customer Experience Implementation Services. Virtusa was one of only three companies to be categorized as a Visionary. According to Gartner, “The CX and CRM implementation service market is completing the shift from the implementation of core CRM technology to complex initiatives that not only transform the front office but integrate across the full enterprise’s operations. Customers now demand that organizations provide them with a continuous experience, preserving continuity of user experience across trad
InnovMetric Launches PolyWorks® Metrology Suite 201922.5.2019 15:00:00 CEST | Pressemelding
Facilitates Deployment of PolyWorks|Inspector™ in Production and Accelerates CNC CMM Measurement Sequences QUEBEC CITY, May 22, 2019 (GLOBE NEWSWIRE) -- InnovMetric Software Inc., the leading provider of universal 3D metrology software solutions, today announced the launch of the 2019 release of the PolyWorks Metrology Suite. This latest major release delivers new object measurement scripts that open the door to all the custom measurement techniques of clients within the standard PolyWorks workflow, as well as a new assisted sequencing approach that promises to greatly accelerate the time to set up CMM sequences. “Simplifying the lives of our customers while keeping them fully in control. This statement embodies the development philosophy behind the PolyWorks Metrology Suite and the latest 2019 release,” said Marc Soucy, President of InnovMetric. He added, “With its outstanding innovations that combine increased simplicity with important time savings, we are proud to bring the producti
Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid22.5.2019 12:55:00 CEST | Pressemelding
BROOKFIELD, May 22, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM) (TSX: BAM.A) (EURONEXT: BAMA) (“Brookfield”) today announced it has received approval from the Toronto Stock Exchange (“TSX”) for the renewal of its normal course issuer bid to purchase up to 82,530,440 Class A Limited Voting Shares (“Class A Shares”), representing 10% of the public float of Brookfield’s outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange (“NYSE”), and/or alternative trading systems. The period of the normal course issuer bid will extend from May 24, 2019 to May 23, 2020, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted. As at May 17, 2019, the number of Class A Shares issued and outstanding totalled 994,568,660, of which 825,304,404 shares represented the pub
Phenom People Launches University Recruiting, SMS & Internal Mobility Chatbot22.5.2019 10:00:00 CEST | Pressemelding
Product Innovations to Support Demand for Talent Experience Management LONDON, May 22, 2019 (GLOBE NEWSWIRE) -- Phenom People, the global leader in Talent Experience Management (TXM), has announced several new features for the Phenom Talent Experience Management platform, adding University Recruiting, SMS, WhatsApp messaging and Internal Mobility chatbot functionality to further support the demands of the new talent economy, which is undergoing major technological and societal shifts. The Phenom Talent Experience Management platform connects the interactions of the four key experiences in the talent lifecycle: candidates, recruiters, employees and management, and delivers a single platform to unify them. Cross-functional insights can be used to power a more personalised and effective experience that meets the demands of today’s talent. The Phenom Talent Experience Management platform furthers chief human resources officers’ top responsibilities across talent acquisition, talent managem